Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Novi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxNovi
Shoppers drawn to the lowest flat headline price in this batch, if they're comfortable that dosing, coverage states, and pharmacy details aren't published anywhere on the site.
Visit NoviThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 69. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Novi still earns a C — Shoppers drawn to the lowest flat headline price in this batch, if they're comfortable that dosing, coverage states, and pharmacy details aren't published anywhere on the site.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Novi |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 69/100 |
| Semaglutide / mo | $99/mo | $99/mo (all doses, promotional rate, compounded) |
| Tirzepatide / mo | $149/mo | $133/mo (all doses, promotional rate, compounded) |
| Semaglutide / yr (modeled) | $1,188 | $1,188 |
| Tirzepatide / yr (modeled) | $1,788 | $1,596 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #1 | #105 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
Novi
69/100Where the value is
- Lowest advertised entry price in this entire batch for both drugs ($99 semaglutide / $133 tirzepatide)
- LegitScript certified, independently verifiable via the linked legitscript.com record
- States one flat price per dose with no separate visit fee and free shipping
The tradeoffs
- No published mg dose, supply duration, state-coverage list, named medical director, or named compounding pharmacy anywhere on the site or its help center — the least transparent operational disclosure of any company researched in this batch
- The advertised $99/$133 rate is displayed against a live countdown timer ('price increases in...') next to a claimed $299 original price, a scarcity tactic that makes it unclear whether this is a genuine standing rate or a recurring promotional one
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.